Wexford Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Wexford Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9,139	Closed	-$158K	–	403
2025 Q2	$158K	Buy	+9,139	New	+$169K	0.04%	188

Other funds holding APLS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wexford Capital's APLS Position: Q3 2025 in Review

Wexford Capital sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 9,139 shares — an estimated $158K sold.

Wexford Capital first reported a position in APLS in Q2 2025 and held it in 1 quarter. The position peaked at $158K in Q2 2025. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

Wexford Capital reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Wexford Capital sold 9,139 Apellis Pharmaceuticals shares in Q3 2025, an estimated $158K.
Wexford Capital first reported a position in Apellis Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Wexford Capital's Apellis Pharmaceuticals position peaked at $158K in Q2 2025.
273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Wexford Capital's 13F filing for Q3 2025, filed 14 Nov 2025.